这家药企心血管布局落关键子:创新药IND获受理

动脉网
Nov 07

11月4日,宜明昂科宣布其自主研发的核心产品替达派西普针对动脉粥样硬化适应症的临床研究申请获NMPA受理,全球患者有望迎来首个靶向CD47的创新治疗方案。动脉粥样硬化是心血管疾病核心病理基础,发病率攀升,传统疗法无法清除已形成斑块,且特异性治疗手段匮乏,存在巨大未满足医疗需求。替达派西普作为创新型CD47靶向SIRPα-Fc融合蛋白,可激活先天免疫系统,实现斑块清除与稳定,疗效优于对照药物。其通过...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10